ResearcherQazvin University of Medical SciencesNo recent work listed
Mehdi Sahmani
Matched on ORCID iD 0000-0002-0069-8803; OpenAlex author ID A5090193450.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 3 (first author 0, last author 1)
- Pancreatic cancer trials
- 0
- Pancreatic cancer grants
- 0
- Collaborators
- 4
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper
Papers 3
- Omega-3 PUFA Alters the Expression Level but Not the Methylation Pattern of the WIF1 Gene Promoter in a Pancreatic Cancer Cell Line (MIA PaCa-2). Co-author DOI 10.1007/s10528-018-9895-0↗
- Effect of PPARδ agonist on stearoyl-CoA desaturase 1 in human pancreatic cancer cells: role of MEK/ERK1/2 pathway. Co-author DOI 10.1016/j.jcjd.2014.09.006↗
- Transcriptional regulation of Δ6-desaturase by peroxisome proliferative-activated receptor δ agonist in human pancreatic cancer cells: role of MEK/ERK1/2 pathw… Last author DOI 10.1155/2013/607524↗
Closest collaborators
The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Babak Rahmani · 1 shared paper, 2019
- Nematollah Gheibi · 1 shared paper, 2019
- Shima Byagowi · 2 shared papers, 2013–2015
- Paper Effect of PPARδ agonist on stearoyl-CoA desaturase 1 in human pancreatic cancer cells: role of MEK/ERK1/2 pathway. DOI 10.1016/j.jcjd.2014.09.006↗
- Paper Transcriptional regulation of Δ6-desaturase by peroxisome proliferative-activated receptor δ agonist in human pancreati… DOI 10.1155/2013/607524↗
- Maryam Darabi amin · 2 shared papers, 2013–2015
- Paper Effect of PPARδ agonist on stearoyl-CoA desaturase 1 in human pancreatic cancer cells: role of MEK/ERK1/2 pathway. DOI 10.1016/j.jcjd.2014.09.006↗
- Paper Transcriptional regulation of Δ6-desaturase by peroxisome proliferative-activated receptor δ agonist in human pancreati… DOI 10.1155/2013/607524↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.